

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	US-2,191,978	2/27/1940	Balle and Horst
	US-2,411,662	11/26/1946	Martin and Gysin
	US-2,516,674	7/25/1950	Havertown and Seifter
	US-2,548,863	4/17/1951	Havertown and Seifter
	US-3,985,891	10/12/1976	Kutter et al.
	US-4,358,387	11/9/1982	Zoleski et al.
	US-4,565,816	1/21/1986	Neumann
	US-4,692,443	9/8/1987	Katner
	US-4,804,658	2/14/1989	Manley et al.
	US-4,914,108	4/3/1990	Khanna et al.
	US-4,988,707	1/29/1991	Stealey et al.
	US-5,019,581	5/28/1991	Khanna et al.
	US-5,057,517	10/15/1991	Johnston et al.
	US-5,208,242	5/4/1993	Khanna et al.
	US-5,332,744	7/26/1994	Chakravarty et al.
	US-5,374,638	12/20/1994	Dhanoo et al.
	US-5,405,964	4/11/1995	Mederski et al.
	US-5,438,063	8/1/1995	Osswald et al.
	US-5,587,372	12/24/1996	Aszodi et al.
	US-5,607,944	3/4/1997	Liniz et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

U.S. PATENT DOCUMENTS			
	US-5,854,265	12/29/1998	Neville J. Anthony
	US-5,859,035	1/12/1999	Anthony et al.
	US-5,872,136	2/16/1999	Anthony et al.
	US-5,874,452	2/23/1999	Neville J. Anthony
	US-5,880,140	3/9/1999	Neville J. Anthony
	US-5,883,105	3/16/1999	Neville J. Anthony
	US-5,939,557	9/17/1999	Anthony et al.
	US-6,051,574	4/18/2000	Neville J. Anthony
	US-6,063,930	5/16/2000	Dinsmore et al.
	US-6,080,870	6/27/2000	Anthony et al.
	US-6,329,381	12/11/2001	Kurimoto et al.
	US-6,376,515	4/23/2002	Zhu et al.
	US-6,479,508	11/12/2002	Beaulieu et al.
	US-6,492,384	12/10/2002	Mederski et al.
	US-2003/0073836	4/17/2003	Priepke et al.
	US-2003/108862	6/12/2003	Kukolj et al.
	US-6,627,651	9/30/2003	Shiraishi
	US-2004/0082635	4/29/2004	Hashimoto et al.
	US-2004/0097438	5/20/2004	Hashimoto et al.
	US-2004/0097574	5/20/2004	Marshall
	US-6,767,654	7/27/2004	Tamao et al.
	US-6,770,666	8/3/2004	Hashimoto et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

U.S. PATENT DOCUMENTS			
	US-20040171626	9/2/2004	Beaulieu et al.
	US-20040186125	9/23/2004	Poupart et al.
	US-6,803,374	10/12/2004	Priestley et al.
	US-6,835,739	12/28/2004	Zhu et al.
	US-6,844,367	1/18/2005	Zhu et al.
	US-20050026921	2/3/2005	Eckhardt et al.
	US-20050096337	5/5/2005	Ackermann et al.
	11/658,625	7/26/2005	Kim et al.
	US-20050222198	10/6/2005	Bondy et al.
	US-20050239821	10/27/2005	Neyts et al.
	US-20060052602	3/9/2006	Kim et al.
	US-7,026,051	4/11/2006	Schauer et al.
	US-7,098,231	8/29/2006	Poupart et al.
	US-7,112,600	9/28/2006	Hashimoto et al.
	US-20060229336	10/12/2006	Kazmierski et al.
	US-20070021472	1/25/2007	Zhu et al.
	US-20070032497	2/8/2007	Hashimoto et al.
	US-7,223,785	5/29/2007	Beaulieu et al.
	US-7,285,551	10/23/2007	Hashimoto et al.
	US-7,294,457	11/13/2007	Kukolj et al.
	12/303,207	2/12/2008	Steven S. Bondy
	US-20080188516	8/7/2008	BONDY et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

U.S. PATENT DOCUMENTS			
	US-20080199427	8/21/2008	Steven S. Bondy
	US-20090036460	2/5/2009	Dowdy et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Applicant	Translation (Yes/No)
	AU-643289	6/14/1991	Callinan Lawrie	
	CA-2093290	7/10/1993	Merck Patent Gmbh	
	CA-2158996	3/14/1994	Bayer Aktiengesellschaft	
	CA-2357771	7/13/2000	Merck Patent Gmbh	
	CA-2423800	3/25/2003	Japan Tobacco Inc	
	CA-2471566	1/7/2003	Boehringer Ingelheim Pharma	
	CA-2496249	8/19/2003	Boehringer Ingelheim Pharma	
	DE-4211474	10/7/1993	Merck Patent Gmbh	
	DE-4230464	3/17/1994	Merck Patent Gmbh	
	DE-4236026	6/16/1994	Merck Patent Gmbh	
	DE-4309969	9/29/1994	Bayer Ag	
	DE-4318813	12/8/1994	Merck Patent Gmbh	
	EP-0138552	4/24/1985	Lilly Co Eli	
	EP-0228845	7/15/1987	Fujisawa Pharmaceutical Co	
	EP-0232937	8/19/1987	Janssen Pharmaceutica Nv	
	EP-0300726	1/25/1989	Merck & Co Inc	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
(37 C.F.R. § 1.98(b))		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
		IDS Filed	June 11, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	EP-0462009	12/18/1991	Roussel Uclaf	
	EP-0510260	10/28/1992	Toyo Jozo Kk	
	EP-0605836	7/13/1994	Meiji Seika Kaisha	
	EP-0706795	4/17/1996	Pfizer	
	EP-1162196	12/12/2001	Japan Tobacco Inc	
	EP-1386923	2/4/2004	Sumitomo Pharma	
	EP-1400241	2/4/2004	Japan Tobacco Inc	
	GB-2264115	8/18/1993	British Bio Technology	
	HU-78019	5/28/1999	Horvath Andras et al.	
	IL-89588	3/13/1989	G.D. Searle & Co.	
	SU-1048742	12/23/1986	Inst Fiz Orch Khim Uglekhiimii et al.	
	SU-813921	12/23/1986	Inst Fiz Orch Khim Uglekhiimii et al.	
	SU-851940	4/30/1988	Inst Fiz Orch Khim Uglekhiimii et al.	
	SU-860463	5/27/1998	Inst Fiz Orch Khim I Uglekhiimii et al.	
	WO-00/20400	4/13/2000	Axys Pharm Inc et al.	
	WO-00/20416	4/13/2000	Merck Patent Gmbh et al.	
	WO-00/20425	4/13/2000	Rhone Poulenc Chimie et al.	
	WO-00/20445	4/13/2000	Chaux Pascal et al.	
	WO-00/39127	7/6/2000	Du Pont Pharm Co	
	WO-00/40583	7/13/2000	Merck Patent Gmbh et al.	
	WO-00/40586	7/13/2000	Chisso Corp et al.	
	WO-00/73307	12/7/2000	Univ Virginia et al.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	WO-01/60315	8/23/2001	laf Blochem Int et al.	
	WO-01/66526	9/13/2001	Cermol Sa et al.	
	WO-01/85172	11/15/2001	Smithkline Beecham Corp et al.	
	WO-01/95910	12/20/2001	Squibb Bristol Myers Co	
	WO-02/04425	1/17/2002	Boehringer Ingelheim Ca Ltd et al.	
	WO-02/057425	7/25/2002	Merck & Co Inc et al.	
	WO-02/067942	9/6/2002	Smithkline Beecham Corp et al.	
	WO-03/000254	1/3/2003	Japan Tobacco Inc et al.	
	WO-03/004020	1/16/2003	Boehringer Ingelheim Pharma et al.	
	WO-03/007945	1/30/2003	Boehringer Ingelheim Ca Ltd et al.	
	WO-03/010140	2/6/2003	Boehringer Ingelheim Ca Ltd et al.	
	WO-03/010141	2/6/2003	Boehringer Ingelheim Ca Ltd et al.	
	WO-03/014229	2/20/2003	Forsch Pigmente Und Lacke E V et al.	
	WO-03/026587	4/3/2003	Squibb Bristol Myers Co	
	WO-03/057205	7/17/2003	Boehringer Ingelheim Pharma et al.	
	WO-04/018468	3/4/2004	Boehringer Ingelheim Pharma et al.	
	WO-04/019935	3/11/2004	Boehringer Ingelheim Pharma	
	WO-04/033455	4/22/2004	Novo Nordisk As et al.	
	WO-04/043913	5/27/2004	Trimeris Inc	
	WO-04/054974	7/1/2004	Smithkline Beecham Corp et al.	
	WO-04/072243	8/26/2004	Enanta Pharm Inc et al.	
	WO-05/063744	7/14/2005	Leuven K U Res & Dev et al.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	WO-06/029966	3/23/2006	Ciba Sc Holding Ag et al.
	WO-06/033703	3/30/2006	Gilead Sciences Inc et al.
	WO-06/069193	6/29/2006	Gilead Sciences Inc et al.
	WO-08/005519	1/10/2008	Gilead Sciences Inc et al.
	WO-09/009001	1/15/2009	Gilead Sciences Inc et al.
	WO-92/22556	12/23/1992	Cheil Foods & Chem
	WO-93/02080	2/4/1993	British Bio Technology
	WO-93/14072	7/22/1993	British Bio Technology
	WO-93/16075	8/19/1993	British Bio Technology
	WO-94/12461	6/9/1994	Pfizer et al.
	WO-94/29321	12/22/1994	Cheil Foods & Chem
	WO-95/02597	1/26/1995	Minnesota Mining & Mfg
	WO-95/16687	6/22/1995	Abbott Laboratories
	WO-96/11192	4/18/1996	Searle & Co. et al.
	WO-96/15111	5/23/1996	Univ Minnesota

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Akamatsu et al., "New Efficient Route for Solid-Phase Synthesis of Benzimidazole Derivatives," <i>J. Comb. Chem.</i> 4:475-483 (2002).
	Baba et al., "Synergistic Antiviral Effects of Antitherpes Compounds and Human Leukocyte Interferon on Varicella-Zoster Virus <i>In Vitro</i> ," <i>Antimicrobial Agents Chemother.</i> 25:515-517, 1984.
	Baginski et al., "Mechanism of Action of a Pestivirus Antiviral Compound," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97:7981-7986, 2000.
	Barlin and Fenn, "A Carbon-13 Nuclear Magnetic Resonance Study of Protonation in Imidazo[4,5-c]pyridines," <i>Aust. J. Chem.</i> 34:1341-1344 (1981).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814	
		Applicant	Bondy et al.	
		Filing Date	June 4, 2007	
		Group	1625	
(37 C.F.R. § 1.98(b))			IDS Filed	June 11, 2009

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Barlin and Fenn, "The Preparation and 1H NMR Spectra of Some N-Methylpurines and Related Compounds," <i>Aust. J. Chem.</i> 36:633-638 (1983).
Barlin, "Ionisation Constants of Heterocyclic Substances, Part VIII. 1,3,5-Triazindenes," <i>J. Chem. Soc. B: Phys. Org.</i> 4:285-291, 1966.
Barracough et al., "An Adventitious Synthesis of a 5-Methylimidazo[4,5-c]pyridine Derivative," <i>Tet. Lett.</i> 27:5987-6000 (1986).
Barracough et al., "Inotropic "A" Ring Substituted Salmazole and Isomazole Analogues," <i>J. Med. Chem.</i> 33:2231-2239 (1990).
Brown et al., "Purine Analogues as Amplifiers of Phleomycin. V. Thioethers of Several Heterocyclic Systems with One or Two Rings," <i>Aust. J. Chem.</i> 32:2713-2726 (1979).
Chou et al., "Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors," <i>Adv. Enzyme Reg.</i> 22:27-55, 1984.
Cleve et al., "Derivate des Imidazo[4,5-b]- und Imidazo[4,5-c]-Pyridins," <i>Liebigs Ann. Chem.</i> 747:158-171, 1971 (and translation).
Curtin et al., "Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists," <i>J. Med. Chem.</i> 41:74-95 (1998).
Elion et al., "Antagonists of Nucleic Acid Derivatives. VIII. Synergism in Combinations of Biochemically Related Antimetabolites," <i>J. Biol. Chem.</i> 208:477-488, 1954.
Final Rejection, December 16, 2006, US 11/019,830
Final Rejection, March 19, 2007, US 11/316,050
Fletcher et al., "Heterocyclic Systems," <i>Nomenclature of Organic Adv. Ser.</i> pp. 49-64, 1974.
Greenfield et al., "Increase in the Stability and Helical Content of Estrogen Receptor Alpha in the Presence of the Estrogen Response Element: Analysis by Circular Dichroism Spectroscopy," <i>Biochemistry</i> 40:6646-6652, 2001.
Griesser, Chapter 8, The Importance of Solvates (pages 211-230), In the text, Polymorphism: In the Pharmaceutical Industry, Hilfler, 2006
Quillory (in Britain ed.) "Polymorphism etc." NY:marcel Dekker Inc. 1999, 1-2, 183-226
International Preliminary Examination Report (PCT/BE03/00117) (mailed 3 September, 2004).
International Preliminary Report on Patentability for PCT/US2004/043112 dated April 25, 2006.
International Preliminary Report on Patentability for PCT/US2005/026606 dated February 20, 2007.
International Preliminary Report on Patentability for PCT/US2005/046477 dated March 16, 2007.
International Preliminary Report on Patentability for PCT/US2007/015553 dated January 13, 2009.
International Search Report for PCT/BE2003/000117 dated December 16, 2003.
International Search Report for PCT/US2005/026606 dated February 13, 2006.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1825
		IDS Filed	June 11, 2009
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
International Search Report for PCT/US2005/046477 dated June 2, 2006.
International Search Report for PCT/US2007/015553 dated March 6, 2008.
International Search Report for PCT/US2008/008259 dated October 14, 2008.
Jacob III, P., "Resolution of (+/-) 5-Bromonnicotine. Synthesis of (R)- and (S)- Nicotine of High Enantiomeric Purity," <i>J. Org. Chem.</i> 47:4165-4167, 1982.
Johnson, A.W. Invitation to Organic Chemistry 1999 Jones and Bartlett: Missisauga, Canada pg. 24
Jones, Malland Organic Chemistry Norton: New York, 1997, Pg. 84-99
Kariv et al., "Improvement of 'Hit-to-Lead' Optimization by Integration of In Vitro HTS Experimental Models for Early Determination of Pharmacokinetic Properties," <i>Comb. Chem. High Throughput Screen.</i> 5:459-472, 2002.
Kuno et al (1993) "Studies on Cerebral Protective Agents, IV. Synthesis of Novel 4-Arylpiperidine and 4-arylpiperazine Derivatives with Anti-Anoxic Activity," <i>Chem Phar. Bull.</i> 41(1):136-162
Lindenbach et al. (2005) "Unraveling Hepatitis C Virus Replication from Genome to Function," <i>Nature</i> 436:933-938
Lochmüller et al., "Chromatographic Resolution of Enantiomers Selective Review," <i>J. Chromatography</i> 113:283-302, 1975.
Mederski and Pachler, "Synthesis and Structural Assignment of Some N-Substituted Imidazopyridine Derivatives," <i>Tetrahedron</i> 48:10549-10558 (1992).
Montgomery et al., "1-B-D-Arabinofuranosyl, etc.," <i>J. Med. Chem.</i> , 1982,25,98-98.
Non-Final Rejection, December 12, 2008, US 10/519,756
Non-Final Rejection, March 12, 2008, US 11/019,830
Non-Final Rejection, March 25, 2009, US 12/022,557
Non-Final Rejection, October 29, 2008, US 11/825,598
Non-Final Rejection, September 27, 2006, US 11/316,050
Okamoto et al., "Optical Resolution of Dihydropyridine Enantiomers by High-Performance Liquid Chromatography Using PhenylCarbamates of Polysaccharides as a Chiral Stationary Phase," <i>J. Chromatography</i> 513:375-378, 1990.
Paeshuyse et al., "A Novel, Highly Selective, etc.," <i>J of Virology</i> , Jan. 2006, 80(1), 149-160.
Puerstinger et al. "Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors" <i>Bioorganic & Medicinal Chemistry Letters</i> 2006, 16:5345-5349
Puerstinger et al. "Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity" <i>Bioorganic & Medicinal Chemistry Letters</i> 2007, 17:391-393

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/128001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/583,814
		Applicant	Bondy et al.
		Filing Date	June 4, 2007
		Group	1625
(37 C.F.R. § 1.98(b))		IDS Filed	June 11, 2009

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Rigaudy et al., "Fundamental Heterocyclic Systems," <i>Nomenclature of Organic Adv. Ser.</i> pp. 53-76, 1979.
	Robertson et al., "Structure-Activity Relationships of Arylimidazopyridine Cardiotonics: Discovery and Inotropic Activity of 2-[2-Methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine," <i>J. Med. Chem.</i> 28:717-727 (1985).
	Savarino et al., "Spectral Behaviour of Linked Heterocyclic Systems and Related Dyes," <i>Spectrochim. Acta A: Mol. Biomol. Spectrosc.</i> 49A:1379-1393 (1993).
	Self et al. (1991) "Romazarit: A Potential Disease-Modifying Antirheumatic Drug," <i>J. Med. Chem.</i> 34:772-777
	Siddiqui et al., "3-Deaza- and, etc.," <i>J. Med. Chem.</i> , 1995, 38, 1035-1038.
	Stanovnik et al., "Methylation of Heterocyclic Compounds Containing NH, SH, and/or OH Groups by Means of N,N-Dimethylformamide Dimethyl Acetal," <i>Aust. J. Chem.</i> 34:1729-1738 (1981).
	Vassilev et al., "Authentic and Chimeric Full-Length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yield Infectious Transcripts," <i>J. Virol.</i> 71:471-478 (1997).
	Vippagunta et al. "Crystalline Solid" <i>Advanced Drug Delivery Reviews</i> 48:3-26 (2001)
	Wang et al., "Non-Nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase. Crystal Structures and Mechanism of Inhibition," <i>J. Biol. Chem.</i> 278:9489-9495 (2003).
	Written Opinion for PCT/US2005/026606 dated February 13, 2006
	Written Opinion for PCT/US2005/046477 dated June 2, 2006
	Written Opinion for PCT/US2007/015553 dated January 7, 2009
	Zhang, "Inhibitors of Hepatitis C -- A Review of the Recent Patent Literature," <i>IDrugs</i> 5:154-158 (2002).
	Zhang, "Studies on the Synthesis and Single Crystal Structure of 3-methyl-6-(p-methylphenyl) Pyridazine," 2001 <i>Journal of Sichuan Normal University (Natural Science)</i> 24(4):384-386 (and translation)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	